DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events.

Mirjam de With,Gemma Brufau, Laila A van den Berg,Femke M de Man,Marija Trajkovic,Martine F Thijs,Rob Castel,Henricus J Vermeer,Samira El Bouazzaoui, Amber van Hemel,Maja Matic,Ron H J Mathijssen,Sander Bins,Ron H N van Schaik

JCO precision oncology（2022）

Cited 3|Views10

No score

Abstract

In this study, the clinical consequences of carrying the *7 variant allele were confirmed as 46% of the patients developed severe AEs, even in the presence of initial dose reductions. This underlines the need for prospective studies investigating the required fluoropyrimidine dose for *7 carriers.

Translated text

Key words

severe,fluoropyrimidine-related

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined